<DOC>
	<DOC>NCT00769067</DOC>
	<brief_summary>This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.</brief_summary>
	<brief_title>A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>advanced measurable NonSmall Cell Lung Cancer (NSCLC); progressed after 12 prior chemotherapy; Eastern Cooperative Oncology Group (ECOG) 02; tissue available for future KRAS/ EGFR testing prior Epidermal Growth Factor Receptor (EGFR) targeted therapy; active or untreated Central Nervous System (CNS) metastases;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>second or third line</keyword>
</DOC>